4.7 Article

Is postoperative radiotherapy an essential treatment for nonmetastatic lymphoepithelial carcinoma of the salivary gland?

Journal

RADIOTHERAPY AND ONCOLOGY
Volume 172, Issue -, Pages 76-82

Publisher

ELSEVIER IRELAND LTD
DOI: 10.1016/j.radonc.2022.05.008

Keywords

Lymphoepithelial carcinoma; Salivary gland; Postoperative radiotherapy; Recursive partitioning analysis (RPA)

Ask authors/readers for more resources

This study evaluated the role of postoperative radiotherapy (PORT) in patients with lymphoepithelial carcinoma of salivary gland (LECSG) and provided individualized treatment recommendations. The results showed that PORT had a positive prognostic effect on progression-free survival (PFS) and locoregional control (LRC) of patients. It was found to be especially beneficial for patients with a primary tumor diameter larger than 3 cm and/or more than 2 positive lymph nodes.
Background: Lymphoepithelial carcinoma of salivary gland (LECSG) is a rare malignant tumor. Whether postoperative radiotherapy (PORT) can improve locoregional control and which patients can benefit from PORT are unknown. This study aimed to evaluate the role of PORT and provide individualized suggestions for postoperative therapy in patients with LECSG.Patients and methods: We retrospectively reviewed patients with nonmetastatic LECSG who underwent surgery with or without PORT. Recursive partitioning analysis (RPA) was performed to categorize the patients and predict progression-free survival (PFS).Results: A total of 223 patients were included, 34 (15.2%) received surgery alone, whereas the remaining 189 (84.8%) underwent PORT in the initial treatment. Although patients in the PORT group were with advanced T stage and N stage, the PORT group had an advantage over the non-PORT group on 1-year, 5-year and 10-year PFS and locoregional control (LRC). PORT was an independent prognostic factor for PFS and LRC. Furthermore, compared with T stage and N stage, the size of the primary tumor and the number of positive lymph nodes were better prognostic predictors. The RPA model was generated according to the endpoint of PFS and categorized patients into 3 prognostic groups: low-risk (maximum diameter of primary lesion (<3 cm) and number of positive lymph nodes (<2)), intermediate-risk (maximum diameter of primary lesion (>3 cm) and number of positive lymph nodes (<2)), and high-risk (number of positive lymph nodes (>2)), with corresponding 5-year PFS rates of 90.0%, 75.0%, and 51.0%, respectively. Significant improvement in PFS was observed in the PORT group among intermediate-risk (P = 0.000) and high-risk patients (P = 0.000).Conclusions: PORT was shown to be a positive prognostic factor for PFS and LRC of LECSG. PORT was an essential treatment especially for patients with >3 cm maximum diameter of primary lesion and/or >2 positive lymph nodes.(c) 2022 The Authors. Published by Elsevier B.V. Radiotherapy and Oncology 172 (2022) 76-82

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available